Renal Cell Carcinoma
Trials for advanced renal cell carcinoma often use restrictive eligibility criteria
Many contemporary clinical trials for metastatic renal cell carcinoma incorporate restrictive eligibility criteria, according to study results.
Artificial intelligence may help predict cardiotoxicity in renal cell carcinoma
Artificial intelligence models can help predict cardiotoxicity risk among patients with renal cell carcinoma treated with VEGF receptor inhibitors, according to study results.
End-stage renal disease after renal cell carcinoma linked to shorter survival
Risk for new-onset end-stage renal disease is considerably higher after treatment for renal cell carcinoma, according to results of a nationwide population-based study.
Exercise linked to better mental, physical health among those with kidney cancer
Physical activity or exercise appeared associated with improved mental and physical health among people with kidney cancer, according to study results.
Immunotherapy combo fails to extend disease-free survival in high-risk kidney cancer
The combination of nivolumab and ipilimumab after nephrectomy failed to extend DFS among patients with localized renal cell carcinoma at high risk for relapse, results of the phase 3 CheckMate 914 trial showed.
Cabozantinib regimen ‘beat the doublet in PFS’ in untreated advanced kidney cancer
Cabozantinib plus nivolumab and ipilimumab conferred a significant PFS benefit vs. nivolumab and ipilimumab alone among patients with advanced renal cell carcinoma, according to results of the COSMIC-313 trial presented at ESMO Congress.
Major adverse cardiovascular event risk higher with targeted therapies for kidney cancer
Targeted cancer therapy had a higher association with risk for major adverse cardiovascular events than cytokine therapy among patients with advanced renal cell carcinoma, according to study results.